ADVA
ADVA (FSE: ADV) today announced that POST Luxembourg has deployed ADVA’s Oscilloquartz optical cesium atomic clock to protect its GNSS-based timing network from jamming and spoofing cyberattacks. The country’s leading provider of ICT and telecom services is utilizing the aPNT+™ technology to meet the synchronization requirements of 5G mobile connectivity and next-generation enterprise cloud applications. With its high availability and unrivaled holdover, the optical cesium atomic clock solution ensures the accuracy and stability needed for the most stringent telecom applications. The solution integrated easily into POST Luxembourg’s existing network management system and is remotely controlled and assured by the ADVA Ensemble Controller with Sync Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220704005303/en/
“With this deployment, we’re injecting new levels of precision, stability, resiliency and holdover into our synchronization network. It’s an important step as we look to meet stricter timing requirements driven by emerging applications. ADVA’s Oscilloquartz optical cesium atomic clock empowers us to support our enterprise customers as they harness new industry digitalization opportunities. It’s also a key tool as we move into the next phase of 5G mobile provision,” said Pierre Scholtes, head of telecom networks, POST Luxembourg. “In recent years, we’ve developed a very strong relationship with ADVA’s team. When it came to enhancing and protecting our timing infrastructure for the future, that mutual trust and close support was just as important as the capabilities and performance of ADVA’s technology.”
ADVA’s coreSync OSA 3350 ePRC+™ is now enabling POST Luxembourg to outperform even the most stringent recommendations for the precision and stability of frequency, phase and time. Deployed in the core of the service provider’s timing network, it’s the ideal backup for satellite-based synchronization and the best defense against GNSS jamming and spoofing attacks. The coreSync OSA 3350 ePRC+™ is the first commercial optical cesium atomic clock specifically designed for ePRC applications that require outstanding stability and resiliency. It offers enhanced holdover compared with standard magnetic cesium clocks. When combined with an OSA grandmaster clock combiner solution to create an enhanced primary reference time clock (ePRTC) system, it provides holdover stability under 35ns for more than 14 days. This is significantly better than the ITU ePRTC specification, which requires no more than 70ns from UTC after a 14-day period.
“Our market-first optical cesium atomic clock is now delivering phenomenal holdover and protecting timing integrity throughout POST Luxembourg’s network. For customers across the Benelux region, it opens the door to a world of new applications that require extremely high reliability as well as very low latency,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “Complementing satellite-based synchronization solutions with ultra-stable atomic clocks is the best available way to safeguard against GNSS vulnerabilities and meet new requirements for precision and availability. POST Luxembourg is once again leading the way in Europe by adopting the most advanced innovation so it can continue to outperform customer expectations.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005303/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom